Compare STRIDES PHARMA SCIENCE with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs PANACEA BIOTECH - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE PANACEA BIOTECH STRIDES PHARMA SCIENCE/
PANACEA BIOTECH
 
P/E (TTM) x 16.4 8.9 183.8% View Chart
P/BV x 1.0 3.5 29.0% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   PANACEA BIOTECH
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
PANACEA BIOTECH
Mar-19
STRIDES PHARMA SCIENCE/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,147354 324.4%   
Low Rs642138 464.5%   
Sales per share (Unadj.) Rs317.274.6 425.5%  
Earnings per share (Unadj.) Rs7.86.7 117.4%  
Cash flow per share (Unadj.) Rs25.115.5 161.7%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.357.2 479.4%  
Shares outstanding (eoy) m89.5061.25 146.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.3 85.5%   
Avg P/E ratio x114.036.8 309.7%  
P/CF ratio (eoy) x35.715.9 225.0%  
Price / Book Value ratio x3.34.3 75.9%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,05815,061 531.5%   
No. of employees `0002.52.3 108.3%   
Total wages/salary Rs m4,3411,471 295.1%   
Avg. sales/employee Rs Th11,325.81,973.6 573.9%   
Avg. wages/employee Rs Th1,731.4635.6 272.4%   
Avg. net profit/employee Rs Th280.1176.8 158.4%   
INCOME DATA
Net Sales Rs m28,3944,567 621.7%  
Other income Rs m94145 2,099.6%   
Total revenues Rs m29,3344,612 636.1%   
Gross profit Rs m3,9652,030 195.4%  
Depreciation Rs m1,540540 285.3%   
Interest Rs m1,9621,048 187.2%   
Profit before tax Rs m1,403486 288.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m9777 126.2%   
Profit after tax Rs m702409 171.6%  
Gross profit margin %14.044.4 31.4%  
Effective tax rate %6.915.9 43.7%   
Net profit margin %2.59.0 27.6%  
BALANCE SHEET DATA
Current assets Rs m24,8362,415 1,028.6%   
Current liabilities Rs m18,9939,077 209.2%   
Net working cap to sales %20.6-145.9 -14.1%  
Current ratio x1.30.3 491.6%  
Inventory Days Days7165 109.0%  
Debtors Days Days11371 159.9%  
Net fixed assets Rs m34,2898,333 411.5%   
Share capital Rs m89561 1,460.0%   
"Free" reserves Rs m23,6513,443 687.0%   
Net worth Rs m24,5463,504 700.5%   
Long term debt Rs m15,513461 3,363.7%   
Total assets Rs m65,43713,755 475.7%  
Interest coverage x1.71.5 117.2%   
Debt to equity ratio x0.60.1 480.2%  
Sales to assets ratio x0.40.3 130.7%   
Return on assets %4.110.6 38.4%  
Return on equity %2.911.7 24.5%  
Return on capital %6.938.7 17.8%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m15,6971,203 1,304.8%   
Fx outflow Rs m735467 157.6%   
Net fx Rs m14,962736 2,031.8%   
CASH FLOW
From Operations Rs m1,8711,049 178.4%  
From Investments Rs m5,826-54 -10,889.5%  
From Financial Activity Rs m-10,157-1,011 1,004.2%  
Net Cashflow Rs m-2,615-20 13,273.6%  

Share Holding

Indian Promoters % 27.7 74.5 37.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.6 6,300.0%  
FIIs % 8.6 1.3 661.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 23.6 109.7%  
Shareholders   56,241 10,259 548.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  ELDER PHARMA  ALEMBIC LTD  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 3, 2020 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - LUPIN COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS